Which types of genetic mutations are larotrectinib (Vitaika) suitable for patients with?

Larotrectinib (trade name Vitrakvi) is an oral, highly selective TRK inhibitor, mainly used to treat patients with advanced or metastatic solid tumors carrying NTRK gene fusions. NTRKgenes include NTRK1, NTRK2 and NTRK3, which after abnormal fusion in tumor cells, will continue to activate the TRK protein and promote the proliferation and survival of tumor cells. Larotrectinib can specifically inhibit the kinase activity of these abnormal fusion proteins, thereby inhibiting tumor growth. Therefore, the use of this drug is not limited to specific cancer types, but uses gene fusion status as the core indication.

Patients suitable for larotrectinib are mainly individuals with NTRK gene fusion confirmed by molecular testing. Such patients may originate from a variety of tumor types, including non-small cell lung cancer, breast cancer, thyroid cancer, colorectal cancer, soft tissue sarcoma, etc. Regardless of whether the patient is a child or an adult, as long as molecular testing shows the presence of NTRK fusion, all patients may benefit from larotrectinib treatment. This "tissue-independent" targeted therapy strategy makes larotrectinib an important drug in the field of precision medicine.

It should be noted that larotrectinib mainly targets NTRK fusions, not point mutations or other types of genetic abnormalities. Therefore, larotrectinib may have limited efficacy in patients with only NTRK gene point mutations or amplifications. In clinical practice, doctors usually recommend that patients undergo molecular testing such as NGS (next generation sequencing) or FISH to determine whether there is NTRK fusion and determine whether larotrectinib is suitable for use.

In addition, larotrectinib has shown significant efficacy in some clinical trials. In patients with NTRK fusion-positive advanced solid tumors, regardless of tumor type, the objective response rate (ORR) can reach 70% or more, and the median progression-free survival and overall survival also show certain advantages. This means that for patients with the right genetic background, larotrectinib can not only delay disease progression but also improve quality of life. Therefore, clarifying the gene fusion status is a key prerequisite for precise treatment with larotrectinib.

Reference link:https://www.drugs.com